Telangiectatic_osteogenic_sarcoma_of_the_extremities._Results_in_17_patients_treated_with_neoadjuvant_chemotherapy._Seventeen_patients_with_telangiectatic_osteogenic_sarcoma_(TOS)_of_the_extremities_were_treated_with_neoadjuvant_chemotherapy,_according_to_two_different_protocols._Preoperatively,_the_patients_received_high-dose_methotrexate_(HD-MTX)_and_cisplatinum_(CPD)_(HD-MTX/CPD)_and_doxorubicin._CPD_was_delivered_intraarterially,_the_other_drugs_intravenously._Limb-salvage_surgery_was_performed_in_12_instances,_and_five_patients_were_treated_with_amputation._Postoperative_chemotherapy_was_tailored_according_to_the_grade_of_chemotherapy-induced_necrosis._In_13_cases_(86%),_the_resultant_grade_of_necrosis_was_greater_than_90%_(good_responders)._The_mean_follow-up_interval_was_3.5_years_with_a_range_of_18_to_78_months._Fourteen_patients_(82%)_remained_continuously_disease-free,_while_three_patients_developed_lung_metastases._Two_of_these_died_because_of_uncontrolled_disease,_whereas_the_third_patient_is_alive_and_disease-free_after_metastasectomy._No_local_recurrences_were_observed._These_results_are_better_than_those_observed_in_215_contemporary_cases_of_conventional_osteosarcoma_treated_with_the_same_protocols._This_study_confirms_that_TOS_is_not_a_uniformly_lethal_tumor_as_suggested_by_prior_reports._By_employing_neoadjuvant_chemotherapy,_a_high_percentage_of_patients_with_TOS_can_be_cured,_and_in_most_of_them,_a_limb-sparing_surgery_is_possible_and_safe.